Virginia is currently home to 1852 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Carcinoma, Non-Small-Cell Lung
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: the recommended dose for Phase 2 to evaluate the safety and tolerability of the combination therapy to determine the pharmacokinetics of TNG260 to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: NEXT Oncology Virginia, Fairfax, Virginia
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Recruiting
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Metastatic Castrate-sensitive Prostate Cancer
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Recruiting
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Gender:
All
Ages:
55 years and above
Trial Updated:
03/25/2024
Locations: Sana Research, Arlington, Virginia
Conditions: Dementia With Lewy Bodies
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruiting
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and prednisone. About 150 participants with mCRPC will be enrolled. Participants will be randomized in a 2:1 ratio to receive lorigerlimab with docetaxel and prednisone (experimental arm) or docetaxel and prednisone alone (standar... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: University of Virginia Health System Cancer Center, Charlottesville, Virginia
Conditions: Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
All
Ages:
Between 18 years and 63 years
Trial Updated:
03/25/2024
Locations: Carilion Clinic /ID# 253374, Roanoke, Virginia
Conditions: Systemic Lupus Erythematosus
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Recruiting
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossove... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/25/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Recruiting
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Carcinoma, Non-Small-Cell Lung
Study of Novel Treatment Combinations in Patients With Lung Cancer
Recruiting
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous trea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: US Oncology Investigational Products Center (IPC),Substudy-01, Fairfax, Virginia
Conditions: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an... Read More
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
03/25/2024
Locations: University of Virginia Cancer Center - West Complex /ID# 225433, Charlottesville, Virginia
Conditions: Diffuse Large B-Cell Lymphoma
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
Recruiting
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/25/2024
Locations: Research Site, Charlottesville, Virginia
Conditions: Asthma